32 citations
,
August 2016 in “Science Signaling” Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.
1 citations
,
February 2025 in “Journal of the Neurological Sciences” Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.
9 citations
,
March 2017 in “Journal of Visualized Experiments” The assay effectively identifies compounds that affect immune cell activation.
January 2011 in “Junshi yixue” A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
Belimumab effectively controls SLE disease activity and reduces steroid use.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
2 citations
,
January 1994 in “Nihon Chikusan Gakkaiho” Cow colostrum and milk can effectively produce anti-hair keratin antibodies.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
159 citations
,
October 1986 in “The Histochemical Journal”
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
7 citations
,
February 2010 in “British Journal of Dermatology” A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
11 citations
,
May 2011 in “The Journal of Dermatology” A man had two rare autoimmune diseases that might be connected.
7 citations
,
February 2015 in “Journal of comparative pathology” CD8+ T cells play a key role in graft-versus-host disease in certain mice models.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
4 citations
,
January 2012 in “Chemical Immunology” Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
November 2024 in “Journal of Investigative Dermatology” 3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.